Beijing Biocytogen Co., Ltd.
Beijing Biocytogen Co., Ltd., an advanced biotechnology company located in Beijing’s Economic and Technological Development Zone, was founded in November 2009 by a team of scientists who have multiple years’ experience developing animal models and operating Biocytogen USA. Biocytogen’s goal is to become the leading gene targeted animal model and service supplier globally. Biocytogen efficiently integrates the advanced capabilities and resources available in both China and the USA. Biocytogen has established two excellent gene-targeting platforms. The first is a traditional ESC/HR platform that includes a unique gene targeting vector construction technology with an accurate micro-injection system and high germline transmission efficiency of C57BL/6 mouse embryonic stem cells (ESC). Our second cutting-edge platform is the Extreme Genome Editing (EGE®) system evolved from standard CRISPR/Cas9 technology. EGE® technology increases large fragment knockin efficiency by 10-20 fold for multiple gene editing designs in cell lines, rats, mice and other species at low cost. As of August 2016, Biocytogen has developed over 1, 500 knockout/knockin mice and rats, and 300 knockout/knockin cell lines based on these two service platforms. Moreover, we helped to develop 4 species of non-human primates in collaboration with partners in several research institutions. As a result, Biocytogen has become one of the leading gene-targeting companies in the world.
In 2015, animal facilities at our Beijing and Jiangsu Haimen Animal Centers were expanded (with a combined area of over 10,000 m2 ) to support our company’s rapid growth. Our services extend from the preparation of gene engineered animals to large-scale supply of animal models. We also offer preclinical animal studies using gene humanized models, PDX models, and human immune system reconstruction models. Our Immuno-Oncology drug service platform is based on immunodeficient animals with human immune system reconstruction (B-NDG mice) and human immune checkpoint gene knockin models (e.g. B-hPD-1 mice). Biocytogen has established a global technical service network which relies on our unique technical platforms, standard operation procedures, strict quality control systems, talented team members, and an efficient executive force. Our customers are from academic institutions such as Harvard University, NIH, University of Tokyo, University of Oxford, Peking University, Tsinghua University, and the Chinese Academy of Sciences. Our clients also include hospitals (Massachusetts General Hospital , Union Hospital, Peking University Hospital, etc.) and international companies such as Johnson and Johnson, Roche, GSK, Merck.
Biocytogen Jiangsu Co.,Ltd.
Biocytogen Jiangsu Co.,Ltd (Biocytogen Haimen Animal Center) is located at the Linjiang New District, Haimen City, Jiangsu Province, P.R.China, close to the Shanghai Zhangjiang High-Tech Park.
Haimen Animal Center is a specific pathogen free (SPF) barrier facility. This 15,000 square meter facility is AAALAC accredited and PHS assured. Led by an extensively experienced team, the Haimen site is primarily dedicated to the mass production of Biocytogen's highly immune deficient (B-NDG) mouse model and a series of immune checkpoint humanized mouse models (B-hPD-1, B-hCTLA4, B-hOX40, etc). Biocytogen offers tumor immunotherapy services for preclinical pharmacological and pharmacodynamic studies. We have completed numerous in vivo efficacy studies for anti-PD-1 and PD-L1 drugs and have assisted pharmaceutical companies in attaining clinical trial approval status and INDs.